^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pradusinstobart (LVGN3616)

    i
    Other names: LVGN3616, LVGN 3616, LVGN-3616
    Associations

    News

    Trials
    Company:
    Lyvgen
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=352, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    CD40 (CD40 Molecule)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    18d
    Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Lyvgen Biopharma Holdings Limited | Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    4ms
    CD40 Agonist and PD-1 Inhibitor in HNSCC (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dalnicastobart (LVGN7409) • pradusinstobart (LVGN3616)
    12ms
    CD40 Agonist and PD-1 Inhibitor in HNSCC (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    dalnicastobart (LVGN7409) • pradusinstobart (LVGN3616)
    1year
    Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=352, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2023 --> Feb 2027 | Trial primary completion date: Jul 2023 --> Feb 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CD40 (CD40 Molecule)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    almost3years
    Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=352, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Nov 2021
    Enrollment open • Trial initiation date • Combination therapy
    |
    CD40 (CD40 Molecule)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    3years
    Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=352, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Combination therapy
    |
    CD40 (CD40 Molecule)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)